التفاصيل البيبلوغرافية
| العنوان: |
PS997 A NEW BIOMARKER OF RESPONSE TO 5‐AZACITIDINE THERAPY IN MDS AND AML PATIENTS: SIRPB1 |
| المؤلفون: |
Cerchione, C., Guadagnuolo, V., Papayannidis, C., Iacobucci, I., Padella, A., Simonetti, G., Paolini, S., Abbenante, M., Parisi, S., Volpato, F., Fontana, M.C., Ottaviani, E., Testoni, N., Baldazzi, C., Delledonne, M., Filì, C., Malagola, M., Cattina, F., Bernardi, S., Russo, D., Martinelli, G. |
| المصدر: |
HemaSphere ; volume 3, issue S1, page 448-449 ; ISSN 2572-9241 2572-9241 |
| بيانات النشر: |
Wiley |
| سنة النشر: |
2019 |
| المجموعة: |
Wiley Online Library (Open Access Articles via Crossref) |
| الوصف: |
Background: Myelodisplastic syndromes (MDS) and Acute Myeloid Leukemia (AML) are a group of diseases of the elderly that initiates in a hematopoietic stem cell and are characterized by clonal hematopoiesis and uncertain prognosis, mostly due to cytogenetic background. In both diseases, 5‐Azacitidine (5‐Aza) has been successful, inducing prolonged survival and delayed AML evolution. Aims: To identify the genes mostly predictive of treatment response, we use high‐throughput genomic analysis (SNP arrays and/or NGS‐RNA‐seq and/or NGS‐WES and/or GEP) in azacitidine‐sensitive and resistant MDS/AML patients. Methods: NGS‐WES or RNA seq HiSeq 2000 (Illumina) was positively done in 35/214 AML samples (16%), GEP (GeneChip Human Transcriptome Array 2.0, Affymetrix Inc.) was performed in 65/214 AML samples (30%). SNPs arrays (CytoScan HD Array, Affymetrix Inc.) in 125/214 AML samples (58%) and 18/32 MDS samples (56%) at diagnosis, then analyzed by Chromosome Analysis Suite (ChAS) v1.2 (Affymetrix Inc.), Nexus Copy Number™ v7.5 (BioDiscovery) and GeneGo MetaCore™ software. Results: We treated 246 adult pts with MDS or AML: 214 were AML and 32 were MDS with a median age of 59 and 70 years, respectively. 45 were treated with 5‐Aza (32 MDS/13 AML), while 201 AML with conventional chemotherapy. 45 MDS/AML were treated with at least one complete cycle of 5‐Aza (75 mg/sqm/daily). SNP arrays was done in 22/45 (49%), 13 pts were defined “insensitive/resistant”, ie. never achieving clinical complete remission (CCR) and 9 were defined “sensitive”, ie. all of them obtaining CCR. Copy Number Alterations (CNAs) ranged from loss or gain of complete chr arms to focal deletions and gains targeting one or few genes involving macroscopic (>1.5 Mbps), submicroscopic genomic intervals (50 Kbps‐1.5 Mbps) and LOH (>5 Mbps) events. Macroscopic CNAs affecting a complete chromosome or its arms were detected in 5 of 22 pts (23%), while classical cytogenetic was able to detect only two cases of trisomy 8 (9%), suggesting superiority of SNPs ... |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| DOI: |
10.1097/01.hs9.0000562284.64194.76 |
| DOI: |
10.1097/01.HS9.0000562284.64194.76 |
| الإتاحة: |
https://doi.org/10.1097/01.hs9.0000562284.64194.76Test |
| حقوق: |
http://onlinelibrary.wiley.com/termsAndConditions#vorTest |
| رقم الانضمام: |
edsbas.80577F83 |
| قاعدة البيانات: |
BASE |
